35. Pemphigus Clinical trials / Disease details

Clinical trials : 99 / Drugs : 124 - (DrugBank : 36) / Drug target genes : 23 - Drug target pathways : 169

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01974518 (ClinicalTrials.gov)	November 2013	4/10/2013	Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus	A PILOT STUDY TO ASSESS THE EFFICACY OF RITUXIMAB VERSUS COMBINATION OF RITUXIMAB AND INTRAVENOUS CYCLOPHOSPHAMIDE IN THE TREATMENT OF REFRACTORY PEMPHIGUS	Pemphigus	Drug: Rituximab and Cyclophosphamide IV	Uprety Shraddha	Postgraduate Institute of Medical Education and Research	Active, not recruiting	18 Years	N/A	Both	20	Phase 3	India
2	NCT00483119 (ClinicalTrials.gov)	April 2007	5/6/2007	Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus	Phase 2 Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus	Pemphigus Vulgaris	Drug: intravenous immunoglobulin;Drug: cyclophosphamide	New York University School of Medicine	NULL	Terminated	18 Years	85 Years	All	9	Phase 2	United States
3	NCT00278642 (ClinicalTrials.gov)	September 2002	16/1/2006	Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders	High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial	Pemphigus	Biological: Hematopoietic stem cell transplantation	Richard Burt, MD	NULL	Terminated	18 Years	60 Years	Both	1	Phase 1	United States
4	NCT00010413 (ClinicalTrials.gov)	April 1999	2/2/2001	Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus		Pemphigus	Drug: cyclophosphamide;Drug: filgrastim	Johns Hopkins University	NULL	Completed	18 Years	70 Years	Both	35	Phase 2	United States